Although the need for effective long-term follow-up for patients with celiac disease (CD) has been recognized by many expert groups, published practice guidelines have not provided a clear approach for the optimal management of these patients. In an attempt to provide a thoughtful and practical approach for managing these patients, a group of experts in pediatric CD performed a critical review of the available literature in 6 categories associated with CD to develop a set of best practices by using evidencebased data and expert opinion. The 6 categories included the following: bone health, hematologic issues, endocrine problems, liver disease, nutritional issues, and testing. Evidence was assessed by using standardized criteria for evaluating the quality of the data, grade of evidence, and strength of conclusions. Over 600 publications were reviewed, and 172 were chosen for inclusion. The thorough review of the results demonstrated that the quality of the data available was often insufficient to provide unequivocal best practices. However, using the available data and the clinical experience of the panel, a practical framework for the management of children with CD was created. These recommendations were developed by our expert panel and do not necessarily reflect the policy of the American Academy of Pediatrics. The potential usefulness of these best practices is underscored by the fact that consensus, measured by the outcome of anonymous voting, was reached by the panel for 24 of the 25 questions. We hope that these best practices may be useful to the pediatric gastroenterology and larger general pediatric communities.
Dr Snyder organized and coordinated the effort, helped with the conceptualization and design of the study, performed a literature review and the primary data analysis, was an active and voting participant in all of the deliberations related to each topic, and helped to draft the initial manuscript; Dr Butzner helped with conceptualization and design of the analyses, performed the literature review and the primary data analysis on bone health, was an active and voting participant in all of the deliberations related to each topic, and helped to draft the initial manuscript; Dr DeFelice helped with conceptualization and design of the analyses, performed the literature review and the primary data analysis on liver disease, was an active and voting participant in all of the deliberations related to each topic, and helped to draft the initial manuscript; Dr Fasano helped with conceptualization and design of the analyses, performed the literature review and the primary data analysis on the testing and monitoring section, was an active and voting participant in all of the deliberations related to each topic, and helped Celiac disease (CD) is a systemic immune-mediated illness triggered by gluten in genetically susceptible persons and affects ∼1% of the world's population. 1 -4 Although great progress has been made in the diagnosis and management of CD in recent years, 1 -6 important problems still exist. One of the most pressing is the lack of effective long-term management programs to optimize the treatment of CD and the diagnosis and management of associated disease states. 7, 8 The need for effective long-term follow-up to improve compliance and outcomes for patients with CD has been recognized by many expert groups for several reasons. 3 -6 Patients with CD who do not carefully adhere to the gluten-free diet (GFD) appear to have an increased risk of mortality and lower quality of life assessments. 9 -11 In addition, patients with CD often have important nutritional deficiencies and are at increased risk for a variety of associated diseases. 1 -4 Despite this clearly recognized need for effective follow-up for CD, recent reports indicate that such optimal follow-up care is not being provided. 7, 8 Although many practice guidelines have been published in North America and Europe, 3 -6, 12 they have not generated a consensus on when and how to provide effective management of these patients. This is likely due to the fact that few evidence-based data were available to support such management guidelines. The absence of clear recommendations on management may also have been influenced by the extremely dynamic nature of the field of gluten-related disorders in general, and of CD in particular. To help address these issues, a best practices conference was convened to review the available evidence and to provide recommendations about how to follow-up these patients. These recommendations were developed by our expert panel and do not necessarily reflect the policy of the American Academy of Pediatrics.
METHODS
Six acknowledged experts in pediatric CD were chosen to provide a thorough assessment of the data and to develop best practices in 6 topic areas: bone disease, endocrine problems, hematologic issues, liver issues, nutritional problems, and testing to monitor CD activity. The assignment of 1 panel member to each topic area was made by the organizer and moderator (Dr Snyder) based on that person's recognized knowledge of the topic and was made in consultation with North American senior experts in pediatric gastroenterology who were not part of the panel. Each panel member researched and summarized their topic area. The panel met and thoroughly reviewed each topic before evaluating and voting on each best practice. In addition to their expertise, the panel members were chosen to provide a geographic representation of the major pediatric CD programs in the United States and Canada. The number of experts chosen was also influenced by logistic and financial considerations because the project was funded by a nonrestricted grant from a nonprofit organization, the Celiac Disease Program of Children's National Health System. The meeting was convened at Children's National Health Center in Washington, DC, on January 25 and 26, 2013. The goal was to provide a critical review of the management of pediatric CD in North America and to develop a practical set of best practices for the Children's National Health System Celiac Program by using evidence-based data and expert opinion.
Literature Search and Grading the Articles for Quality of Evidence
Each expert completed a thorough literature search combining the term "celiac disease" with multiple terms specific to their section using accessible databases including PubMed, Medline, Embase, Cochrane Library, BioSciences Information Services Previews, EBM Reviews, ISI Web of Science, and Scopus. The search included publications from 1973 to January 2013 and included publications of all types that presented or reviewed data on CD in patients younger than 20 years old. Publications were assessed by using criteria including study design, sample size, data analysis, synthesis of results, potential bias, and limitations.
The search identified over 600 unique publications. Of these 600 articles, 172 were included after exclusion of publications that did not present relevant evidence, that did not present sufficient evidence for pediatric patients, or were commentaries, case reports, abstracts, or nonsystematic reviews. Reviews of the literature were used to find additional primary research references and to provide summaries of data, references for pathophysiology, and to point our team to more extensive background reading. Reviews were also used to support introductory statements. The review articles and guidelines are identified in the References. Only original clinical studies were used to develop the "Best Practice" management questions.
Voting on Best Practice Statements and Grading the Statements for Quality of Evidence
Details about mechanism for anonymous voting, assessment of quality of data, use of the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) system to evaluate the available evidence, and strength of recommendation are included in the Supplemental Information, Part 1. 13
BEST PRACTICES

A. Bone Health
Background
CD can affect the bone health of children in several ways with a variety of signs and symptoms including bone pain, rickets, tetany, osteomalacia, osteopenia, osteoporosis, fractures associated with minimal trauma, or growth failure with or without symptoms of malabsorption. 14 -16 With the exception of osteopenia or osteoporosis identified by the evaluation of bone mineral density, these are now rarely the presenting signs and symptoms of CD in children because of the widespread use of CD serological testing to assist in diagnosis. 14-16 Initiation of a GFD rapidly restores bone mass to normal levels in almost all children and some adolescents. 17 
B. Hematologic Problems
Background CD has been associated with a variety of hematologic disorders, of which anemia is by far the most common. In fact, anemia may be the only clinical abnormality identified in many patients and can be the presenting feature of CD, especially in older children and adults. 50 -54 Anemia in children with CD can be the end result of several different, and sometimes interrelated causes; however, the single most common type of anemia is iron deficiency. 50 Detailed information on anemia, folate deficiency, vitamin B 12 deficiency, anemia of chronic disease, platelet abnormalities, thromboembolic problems, coagulation abnormalities, immunoglobulin (Ig)A deficiency, and splenic dysfunction are included in the Supplemental Information, Part 2B. 50 -72 Best Practice 6
Should screening for anemia using a combination of tests including a complete blood cell (CBC) count (CBC plus evaluation of mean cell volume), ferritin, iron, and total iron-binding capacity be done routinely for all children being evaluated for CD at the time of diagnosis? 
Comment
There is abundant evidence in the literature about the prevalence of anemia, especially irondeficient, in children with CD at the time of diagnosis. 50 -53, 58 This group unanimously supports the measurement of "iron studies" as reported above as an appropriate screening tool, in light of the possible need for replacement.
Best Practice 7
Should a CBC count be obtained routinely for all children undergoing follow-up evaluation for CD? 
C. Endocrine-associated Disorders in CD
Background
Endocrine disorders frequently cooccur with CD, primarily due to their shared HLA predisposition, but the association is also affected by shared non-HLA variants. 73 Autoimmune thyroid disease and type 1 diabetes mellitus (T1DM) are the most common autoimmune diseases that occur with CD but Addison disease, parathyroid disorders, and growth hormone deficiency have also been reported 74 -76 ; however, they are much less common. 84 -88, 90 Screening with thyrotropin is recommended in those with type 1 diabetes, and should be used also in CD. 80 The serum thyrotropin assay is accurate and widely available to screen for all common forms of hypothyroidism and hyperthyroidism. In addition, effective therapies for thyroid disease are available.
Best Practice 12
Should thyroid disease be screened for at the time of follow-up evaluation for children with CD? 
D. The Liver and CD
Background
The liver can be 1 of the major sites for extraintestinal manifestations of CD. A spectrum of liver abnormalities has been described, ranging from elevated aminotransferases (cryptogenic hypertransaminasemia) to celiac hepatitis to autoimmune liver disease. 99 -109 
Comment
The current literature estimates that 30% to 70% of patients with CD are nonresponsive to hepatitis B vaccine before treatment. 112 -120 If this is accurate, a serious public health concern exists. More large-scale studies are needed to validate this estimate.
E. Nutritional Problems and CD
Background
Nutritional problems in CD can occur as a result of intestinal inflammation from the disease process itself and as a consequence of medical nutritional therapy (MNT) with the GFD. It is important to consider this dynamic situation, as nutritional issues at the time of diagnosis may change after implementation of the GFD. Detailed information on anthropometric impact, micronutrient impact, and medical nutrition therapy are included in the Supplemental Information, Part 2E. 121 -155 Best Practice 16 
F. Testing and Monitoring
Diagnostic Tests and Monitoring
Several tests are used to diagnose and monitor CD, including serologic tests, genetic testing, and histology. 1 -6 The current diagnostic algorithm for CD includes initial screening serological tests, followed by a confirmatory small intestinal biopsy revealing the autoimmune insult typical of CD in children and adults. 3 -6 The relative merits of these tests in various situations, including detailed information on initial diagnosis: serology, serology in IgA deficient patients, histology, use of HLA testing, monitoring successful compliance to the GFD, and current guidelines are included 7 
Comment
Most of the studies published, including population studies and studies specifically focused at comparing commercially available assays, report extremely high specificity. 156 -160 However, welldesigned studies to assess sensitivity have not been performed. These studies should be based on the use of endoscopy and histologic analysis as primary standard to validate the sensitivity of these tests.
Best Practice 21
Should IgA anti-tTG antibody be obtained for all children diagnosed with CD at periodic intervals after diagnosis to help monitor compliance with the GFD? 
Comment
There have been several reports with variable data revealing that tTG IgA antibody titers tend to decrease or completely return within normal limits after 6 to 12 months after the implementation of a GFD. 171, 172 However, while tTG IgA ELISA is a validated assay for the diagnosis of CD, this assay has not been validated for monitoring. 164 
Best Practice 22
Should the use of the antiendomysial antibody be limited to patients with comorbidities that increase the chance of false-positive tTG antibodies?
QUALITY 
Comment
There is strong evidence in the literature that ∼10% of celiac cases can test falsely negative to the tTG IgA test. 160 
Best Practice 24
Should HLA typing be considered in the evaluation of children at risk for CD who have negative serology? 
Comment
In the ever growing situation in which children have been placed on a GFD before confirming the diagnosis of CD, the assessment of HLA status can be of great assistance in deciding whether to perform a gluten challenge. 1, 172
SUMMARY
Serious concerns have been raised about the lack of effective long-term management programs to optimize the treatment of CD and the diagnosis and management of associated disease states. 7, 8 Recent reports indicate that optimal follow-up care is not being provided. 7, 8 In an attempt to provide thoughtful and effective best practices for managing CD and associated disorders in children, a group of experts in the field were convened to critically review and discuss the available data to provide an evidenced-based approach to optimal care. When the quality of evidence was not sufficient, expert opinion was used.
The thorough review of the data in these 6 categories of care demonstrated that the quality of the data available is insufficient to provide unequivocal best practices in most areas. However, using the available data and the clinical experience of the panel, we have attempted to provide a practical framework and useful approach to the management of children with CD. The potential usefulness of these best practices is underscored by the fact that consensus, measured by anonymous voting, was reached by the panel for 24 of the 25 questions and that unanimous agreement was found for 15 of the questions. These recommendations, which were developed by our expert panel, do not necessarily reflect the policy of the American Academy of Pediatrics. We hope that these best practices may be useful to the pediatric gastroenterology and larger general pediatric communities.
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